Signaturefd LLC Decreases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Signaturefd LLC lowered its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,902 shares of the company’s stock after selling 222 shares during the period. Signaturefd LLC’s holdings in CRISPR Therapeutics were worth $119,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. CWM LLC grew its stake in shares of CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after purchasing an additional 260 shares during the last quarter. Tradewinds Capital Management LLC lifted its holdings in CRISPR Therapeutics by 545.5% in the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares during the period. Blue Trust Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $32,000. Headlands Technologies LLC bought a new position in shares of CRISPR Therapeutics during the third quarter valued at approximately $34,000. Finally, Bourgeon Capital Management LLC lifted its stake in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $54.83 on Tuesday. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The business has a fifty day moving average of $70.02 and a 200 day moving average of $64.17. The firm has a market capitalization of $4.65 billion, a P/E ratio of -27.97 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. The company’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.41) earnings per share. Analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Raju Prasad sold 3,524 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the sale, the chief financial officer now directly owns 6,476 shares of the company’s stock, valued at approximately $470,740.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,992 shares of company stock worth $6,132,335. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on CRSP. Mizuho boosted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Wells Fargo & Company raised their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Barclays raised their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada increased their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $76.29.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.